Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
Metrics to compare | ONC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipONCPeersSector | |
---|---|---|---|---|
P/E Ratio | 0.0x | −4.0x | −0.7x | |
PEG Ratio | 0.00 | 0.00 | 0.00 | |
Price/Book | 0.0x | −1.8x | 2.6x | |
Price / LTM Sales | 0.0x | 3.4x | 3.2x | |
Upside (Analyst Target) | 0.0% | 131.4% | 43.9% | |
Fair Value Upside | Unlock | −23.6% | 6.5% | Unlock |